We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Rockeby Secures License for Pre-eclampsia Diagnostic Test

By Labmedica staff writers
Posted on 02 Feb 2007
Rockeby Biomed Ltd (Orchard Rd., Singapore) has entered into a world-wide licensing agreement to license a blood test to diagnose pre-eclampsia. This is a common medical disorder of pregnancy, also called pregnancy-induced hypertension. This is subsequent to the test achieving critical milestones in the first phase of its development.

Rockeby, which has been funding the development of the pre-eclampsia test since August 2005, has secured the licensing agreement with the Queensland-based developer of the test Dr. Victor Voroteliak and his company Diagnoz Pty. Ltd.

Rockeby chief executive Dr. Sze Wee Tan said the company would now fund the second round of the development of the test under a new licensing agreement. This test would also add to the Intellectual Property library that the company is acquiring as it develops diagnostic tests for female healthcare needs.

We have entered into a licensing agreement with Dr. Voroteliak to license the pre-eclampsia test in return for a new round of funding up to July 2007, Dr. Tan said. Once we have completed the last development milestone, we can continue to explore external funding for this project, as we have already licensed the rights to the intellectual property from Dr. Voroteliak with this licensing agreement.

Pre-eclampsia is the most common medical disorder of pregnancy with a reported incidence in the obstetric literature, affecting at least 5-8% of all pregnancies. It is a rapidly progressive condition characterized by high blood pressure and the presence of protein in the urine. Swelling, sudden weight gain, headaches, and changes in vision are important symptoms; however, some women with rapidly advancing disease report few symptoms. Diagnosis is currently symptomatic on the basis of sustained blood pressure > 140/90 mmHg in conjunction with proteinuria (American College of Obstetricians and Gynecologists guidelines). Pre-eclampsia, without intervention, progresses to eclampsia, which is characterized by malignant hypertension and epileptiform convulsions requiring emergency Caesarian sections.



Related Links:
Rockeby Biomed

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Immunofluorescence Analyzer
IFA System
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+

Latest Industry News

Qiagen Agrees to Go Private Through EQT-Led Acquisition
02 Feb 2007  |   Industry

Hologic and Inpeco Partner to Advance Molecular Laboratory Automation in Europe
02 Feb 2007  |   Industry

Collaboration to Expand Cervical Cancer Screening Access With At-Home HPV Collection
02 Feb 2007  |   Industry